Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
772.020.12%
QQQ
720.290.11%
BTC/USD
78895.961.711%
DIA
536.330.21%
GLD
422.780.04%
TLT
83.090.04%

SELLAS Life Sciences Group Inc

SLSNASDAQ
Trade with Public
Trade with Public
$14.34
-0.87-5.72%
Last update: Aug 28, 9:55 AM
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareStock Report

SELLAS Life Sciences Gr Analyst Price Targets

Wall Street analyst price targets and consensus rating for SELLAS Life Sciences Gr (SLS).

Price Target Range — 4 Quarters

Analyst Consensus — 2 Analysts

2Buy
Consensus RatingBuy# Analysts2Avg. Consensus PT$7Upside to Avg. PT-54.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Mar 12, 2026Maxim GroupJason McCarthyPT RaiseBuy$7→$10
Jul 16, 2025Maxim GroupJason McCarthyPT RaiseBuy$4→$7
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Maintains Buy on SELLAS Life Sciences Gr, Raises Price Target to $7

Maxim Group analyst Jason McCarthy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and raises the price target from $4 to $7.
Benzinga Newsdesk

Galena Biopharma Upgraded to Buy: Here's What You Should Know

Investors might want to bet on Galena Biopharma, Inc. (NASDAQ: SLS), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.
Zacks

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and maintains $3 price target.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on SELLAS Life Sciences Gr, Maintains $3 Price Target

Cantor Fitzgerald analyst Li Watsek reiterates SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and maintains $3 price target.
Benzinga Newsdesk

PRO
Alliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8

Alliance Global Partners analyst James Molloy maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Buy and lowers the price target from $14 to $8.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on SELLAS Life Sciences Gr, Lowers Price Target to $6

Cantor Fitzgerald analyst Li Watsek maintains SELLAS Life Sciences Gr (NASDAQ:SLS) with a Overweight and lowers the price target from $10 to $6.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved